Drugs / HER-2/neu peptide vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01355393 | Jul 2011 → Nov 2013 | HER2 positive breast carcinoma, male breast carcinoma | University of Washington | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2/neu peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01355393 ↗ |
| Action | Deplete | “to kill tumor cells that express HER-2/neu” NCT01355393 ↗ |
| Route | Other | “administered intradermally (i.d.)” NCT01355393 ↗ |